CA1245931A - Positionable tissue interfacing device for the management of percutaneous conduits - Google Patents
Positionable tissue interfacing device for the management of percutaneous conduitsInfo
- Publication number
- CA1245931A CA1245931A CA000490636A CA490636A CA1245931A CA 1245931 A CA1245931 A CA 1245931A CA 000490636 A CA000490636 A CA 000490636A CA 490636 A CA490636 A CA 490636A CA 1245931 A CA1245931 A CA 1245931A
- Authority
- CA
- Canada
- Prior art keywords
- sleeve
- conduit
- tissue
- percutaneous
- introducer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims description 37
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 230000010339 dilation Effects 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000000515 collagen sponge Substances 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 38
- 238000013461 design Methods 0.000 abstract description 14
- 208000035143 Bacterial infection Diseases 0.000 abstract description 6
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000002500 effect on skin Effects 0.000 abstract description 3
- 206010033675 panniculitis Diseases 0.000 abstract description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 abstract description 2
- 206010011409 Cross infection Diseases 0.000 abstract 1
- 206010029803 Nosocomial infection Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- 239000011148 porous material Substances 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 230000008952 bacterial invasion Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- WRIYPTGFYKBSFU-UHFFFAOYSA-N ()-Conen Chemical compound CCCCOP(=O)(SCC)SCC1=CC=CC=C1 WRIYPTGFYKBSFU-UHFFFAOYSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0261—Means for anchoring port to the body, or ports having a special shape or being made of a specific material to allow easy implantation/integration in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0285—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body with sterilisation means, e.g. antibacterial coatings, disinfecting pads, UV radiation LEDs or heating means in the port
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0291—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body method or device for implanting it in the body
Abstract
A POSITIONABLE TISSUE INTERFACING DEVICE FOR
THE MANAGEMENT OF PERCUTANEOUS CONDUITS
Abstract of the Disclosure This invention is a tissue interface device designed to reduce the incidence of nosocomial infection related to percutaneous conduits by promoting a tissue seal where the conduit and skin interface, and by the expression of antibacterial activity to reduce the possibility of bacteria advancing along the conduit into deeper tissues. In particular, the positionability of the invention allows it to be placed onto a catheter-like device, in the dermal and subcutaneous tissue below the catheter exit site, although this position relative to catheter length is variable at different anatomical sites, and from patient to patient. The positionability design also allows the invention to be used in conjunction with existing percutaneous access devices such as catheters and wound drains, as an optional measure against bacterial infection.
THE MANAGEMENT OF PERCUTANEOUS CONDUITS
Abstract of the Disclosure This invention is a tissue interface device designed to reduce the incidence of nosocomial infection related to percutaneous conduits by promoting a tissue seal where the conduit and skin interface, and by the expression of antibacterial activity to reduce the possibility of bacteria advancing along the conduit into deeper tissues. In particular, the positionability of the invention allows it to be placed onto a catheter-like device, in the dermal and subcutaneous tissue below the catheter exit site, although this position relative to catheter length is variable at different anatomical sites, and from patient to patient. The positionability design also allows the invention to be used in conjunction with existing percutaneous access devices such as catheters and wound drains, as an optional measure against bacterial infection.
Description
1L2~593~
V62:15794/DJM/RRP -1-A POSITIONABLE TISSUE INTERFACING DEVICE FOR
THE MANAGEMENT OF PERCUTANEOUS CONDUITS
Field of the Invention This invention relates to a device for the improved management of microbial invasion associated with percu-taneous conduits, but more particularly to a design which allows the device to be used in conjunction with an existing conduit and positioned along the length of the conduit to the desired anatomical site for optimal effectiveness.
Description of the Prior Art A percutaneous device or conduit is an implement which passes through the skin, allowing the linkage of an intracorporeal organ or cavity with extracorporeal equipment. There exists a wide variety of clinical applications for percutaneous devices. In the facilita-tion of fluid transport, percutaneous conduits, or catheters, are used to access blood for dialysis, pressure monitoring, or laboratory diagnosis, to deliver drugs or nutritional solutions, and to drain wound exudate. Percutaneous electrical leads are used to allow the monitoring of biopotentials from natural organs or implanted instrumentation, as well as for stimulation of such organs.
,' l~ .!
~2~S9~
Des?ite the w-despread clinical need and usage o percutaneous conduits, the presence of the conduit eventually results in bacterial infection, compromising the health of the patient and forcing conduit removal.
Thus, the conduit is implanted through a wound in the skin which may have been made expressly for the purpose of inserting the conduit, or may have been the result of injury. In either case a sinus tract is formed by ingrowth of epithelium into the wound A ~ood review of the biology and failure mechanism~
associated with percutaneous devices can be ~oun~ ln CRC Critical Reviews in Bioengineering, Vol. 5, pp. 37-77, 1981, by A.F. von Recum and J. B. Park.
Bacteria that have penetrated beneath the epithelium-conduit interface into underlying tissues find a favorable environment for colonization. The tissues contacting implanted foreign bodies are in a state of chronic inflammation, impairing the normal deense mechanisms against bacterial infection, a basis for the commonly accepted fact that wounds containing foreign boZies are more susceptible to infection.
(Williams and Road, Implants in Surgery, 2~1-244, W. B.
Saunders Co., Ltd., 1973.) A classic study demonstrated that while 7.5 x 106 viable staph aureus organisms were necessary to ?roduce a skin infection, only 3 x 102 organisms produced an infection in the presence ~2~5931 1 of a silk sti~ch inserted in the wound. ~Elek and Conen, British Journal of Experimental Pathology, 38:573, (1957).] A more recent study has indicated the phagocytosis of bacteria by leukocytes, the secondary defense against bacterial invasion, is impaired in the presence of some foreign materials, at least in vitro.
(Borges, L.F., Neurosurgery, 10:55-60, 1982) Typically, once established, bacterial infections around implanted foreign materials cannot be managed, even with massive antibiotic therapy, forcing removal of the implant.
The advance of bacterial colonization along the conduit surface and interfacing tissues may also result in peritonitis when the peritoneal cavity is penetrated by the conduit. Similarly, joint capsule infection may occur when a wound is drained after orthopedic surgery, and septicemia may result when the vascular system is accessed by an intravenous or arterial line. The constant bacterial challenge and threat of infection created by percutaneous conduits forces conduit removal and replacement in alternate areas when possible, and either discontinuation of the function of the conduit or increased risk of infection when not possible.
The bacterial organisms which initiate infections associated with percutaneous conduits are part of the normal flora on the skin, ranging in density from 10 to 106 organisms per square centimeter. Normally these organisms are unable to colonize illtO deeper tissues and proliferate, as they cannot penetrate the primary barrier against infection, the epidermal layer of the skin. The presence of a percutaneous conduit requires disruption of this barrier, through which bacteria can invadc deeper tissues.
5~
1 The perimeter at the conduit in~erface does not seal, even after sufficient time for wound healing. The new, healing epithelium, upon reaching the condui~, does not recognize and adhere to the foreign body, but instead, grows down along the conduit in an effort to externalize the foreign body, forming a sinus tract, a pathway for bacterial invasion. A recent clinical study has indicated significant association of bacterial colonization of percutaneous catheters and the density of bacteria present on the skin at the exit site, as one would expect from the infection pathway. (Bjornson, et al., Surgery, Vol. 92, No. 4, pp. 720-726, 1982).
The lack of a seal at the conduit to the dermal and epidermal tissues not only allows access for bacteria, but also prevents mechanical loads from being transferred between the tissues and the conduit. The mechanical discontinuity causes a crevice between the tissues and a conduit to open and close when the conduit is mechanically stressed or when the tissues move during normal muscle usage, promoting bacterial invasion.
In order to reduce the ever-present threat of infection associated with percutaneous conduits, devices to improve the tissue interface at the percutaneous area (dermis- and epidermis-conduit interface) have been constructed. The use of porous material which promotes tissue in~rowth in the tissue layers below the epidermis has shown effectiveness in inhibiting epidermal downgrowth (sinus tract formation) and promoting a seal at the epidermal- and dermal-conduit interface. (Lee, U.S. Pat.
3,663,965; Borsany, U.S. Pat. 4,278,092.) However, porous materials with interconnected porosity, such as velours, felts, foams, and sponges, have a disadvantage in that once infected, the material acts as a wick, ~5~3~
l allowing the bacteria to colonize the pores f illed with wound exudate and wound debris, in areas not readily accessible to host defense cells.
Other attempts at combating bacterial infection related to percutaneous conduits involve the application of antibacterial agents, either to the conduit surface (Crossley, U.S. Pat. 4,054,139), or in a fluid reservoir device constructed around the conduit, located in the subcutaneous tissue just below the conduit exit site (Kitrilakis, et al., U.S. Pat. 3,699,956).
Several problems arise when using a tissue inter-facing device at the percutaneous interface to help reduce the incidence of infection. The use of devices which have bulky subcutaneous flanges (Faso, U.S. Pat.
4,217,664) or antibacterial fluid reservoirs (Kitrilakis, supra) require surgical manipulation of tissues to properly place the device. If the device has a tissue sealing design using porous materials, such as a velour sleeve, the material should be located close to the dermis-conduit interface. Misplacement in the intracorporeal direction will allow mechanical discontinuity at the critical dermis-to-conduit interface, and also will not allow the epidermis and dermis to grow into the porous material to provide a bacterial seal. Misplacement in the extra-corporeal direction will create passageways for bacteria through the pores and immediately introduce external skin bacteria to colonize the porous material.
Also, when implanting a percutaneous conduit with an attached percutaneous device, or otherwise designated percutaneous area, the length of conduit frorn the percutaneous exit site to the intracorporeal end is desired to be variable, to allow for the anatomical geometry of the particular patient. Inaccuracies ,, .
3LZ~3~L
involved in estimating tllis length may cause the improper location of the percutaneous tissue-interfacing device in the tissue layers of the integuement, the improper location of the intracorporeal end, undesirable slack in the conduit, or required trial fittings to establish the correct length.
The percutaneous tissue-interfacing device of this invention is easily positionable along the conduit length to provide flexibility for optimal device placement during the surgical procedure. ~dditionally, the ability to be quickly positioned and attached to a pre-existing percu-taneous conduit allows the device to be used as an optional measure for patients at high risk for infection.
Summary of the Invention The invention comprises a tissue interface device designed to be placed onto a separate percutaneous conduit and positioned along the conduit length to a desired anatomical site for effective infection resistanceO The invention can be implemented at the time of conduit implantation, or at a later time at the discretion of the clinical practitioner.
Briefly, the invention comprises a sleeve with elastic properties which is dilated with the aid of a special introducer and is then placed over a conduit or catheter-like device. When the introducer is removed, the elastomeric properties of the sleeve material cause its diameter to decrease resulting in radial compression against the conduit, thus securing the sleeve.
The outer, tissue interfacing 5urface of the device is designed to reduce the incidence of infection related ~ z~g~
1597~ -7-to percutaneous conauits by two basic mechanisms:
(a) promotion of a tissue-to-conduit seal at the skin (epidermis, dermis, and adjacent subcutaneous tissues3 to conduit interface, and (b) the use of antibacterial agents incorporatea into the device to reduce the possibility of bacteria colonizing the foreign materials (especially during the initial ~ormation of ~ tissue seal) and advancing along the conduit into deeper - tissues.
, Description of the ~rawings Fig. 1 shows the anatomical relationship between a percutaneous conduit; the skin and the body sur~ace;
Fig. 2 illustrates the relationship between a conduit, a sleeve and an introaucer;
Fig. 3 shows how a sleeve is positioned by an introducer on a conduit;
Figa 4 shows differently shaped conduits in cross section;
Fig. 5 is a drawing of a conduit with longitudinally placed tissue ingrowth material, Fig. 6 shows one type of introducer;
Fig. 7 illustrates the use of an introducer of the type shown in Figure 6;
Fig. 8 illustrates an alternative embodiment of an introducer;
Fig. 9 shows one alternative embodiment of the sleeve of Figure 2;
Fig. 10 shows another alternative embodiment of a sleeve; and Fig. 11 shows yet another embodiment of a sleeve, where the sleeve is wound around the conduit.
g~2~5~33~
For clarity, Figure 1 depicts the anatomical relationships referred to in the following description of the infection mechanism associated with percutaneous conduits. A conduit 1 is showing spanning the Yarious layers of the skin 2. The portion of the conduit 1 which lies outside the body is referred to as extra-corporeal, while that within the body body is intra-corporeal. Conduit 1 is implanted through a wound in the skin; wound 3 may have been made expressly for the purpose of inserting conduit 1, or it may have been the result of an injury. In either case, a sinus tract 4 is formed by ingrowth of epithelium into the wound.
5~3~
15974 _9_ 1 Description of the Preferred Embodiments Referring to Figure 2, the preferred embodiment device of the present invention includes a sleeve 5, with an inside diameter less than the outside diameter of a conduit, 1. The term "conduit" is used in a general sense to include both hollow tubular catheters and other types of elongated body-insertable members (either solid or hollow) such as electrical leads.
The device is elastically dilated by way of an introducer 6. Introducer 6, which will be described in greater detail below, is inserted into the sleeve 5, and used to expand its diameter. The externally extending conduit end is inserted through the introducer 6 and distended sleeve 5, and the sleeve and introducer are moved longitudinally along this conduit to the desired tissue site. Introducer 6 is then removed, allowing sleeve 5 to return to its normal diameter, leaving the tissue-interfacing sleeve clamped onto the conduit.
Sleeve 5 will typically be located in a subcutaneous position, as illustrated in Figure 3B, where sleeve 5 is shown serving to secure a percutaneous conduit.
Figure 3 illustrates the relationship of conduit 1, sleeve 5 and an alternative embodiment of an introducer 8 ~shown in detail below). In Figure 3A the assembled introducer 8 and sleeve 5 are shown as they are placed over the extracorporeal conc1uit 1 in preparation for positioning. In Figure 3~, sleeve 5 has been positioned with respect to skin 2. Introducer 8, still in place, will be removed, leaving sleeve 5 in place around conduit 1. Although this illustration shows one design of introducer, the same relationships between skin, conduit, sleeve and introducer would obtain were an introducer of a diferent design used.
5~3~
1597~ -~0-1 Essential to the positionability of the device is the elastic property of the sleeve material. This allows high material strain, corresponding to large device dilation, and use of the stored strain energy to provide a radial clamping force upon release~ The high deformability of the elastomeric material also allows sealing of sleeve 5 to the conduit 1, even if the conduit cross-section is ellipsoid (Fig. 4a) or has complex geometry (Fig. 4b, 4c). Any elastomer with negligible stress-relaxation properties and high elastic limit is suitable mechanically. It is also desirable from a physiological viewpoint that the elastic material have minimal inflammatory effect on the surrounding tissue.
Several t~pes of medical grade elastomers, such as polydimethyl siloxanes (silicone rubbers) or related polymers, polyurethanes and polyisoprenes are suitable.
Essential to the infection reduction properties of the invention is the outer, tissue interfacing surface of sleeve 5. The surface is desired to express both antibacterial activity and tissue sealing properties.
The tissue sealing properties can be conferred by (a) the attachment of porous, tissue ingrowth promoting material, such as woven felts, and velours, textured polymers, and foam or sponge-like materials, (2) the surface texturing of the sleeve material by high energy bombardment or salting out methods; (3) the attachment or incorporation of tissue adhesive biomolecules such as lectins.
The antibacterial properties can be conferred by (1) bulk incorporation of antibacterial agent into the sleeve material, (2) surface coating of antibacterial agent, or (3) attachment of a tissue ingrowth promoting material with incorporated antibacterial activity.
593~
1 Generally, the invention will consist of a sleeve 5, with antibacterial surface properties conferred by one of the methods previously described. It is also preferred to have tissue adhesive properties without the use of rclatively permanent porous tissue ingrowth materials.
The use of adhesive biomolecules on the outer surface or biodegradable tissue in9rowth materials such as collagen sponge, or a combination of the two, are preferred, as ease of device removal will not become compromised.
In one embodiment of the present invention, shown in Figure 5, sleeve 5 will have an irregular-surfaced tissue ingrowth material 7, attached placed on the outer surface in longitudinal strips or sufficient radial dilation. The ingrowth of subcutaneous and dermal tissue into the pores will form a seal around the conduit, reducing the sinus tract pathway for bacterial invasion around the catheter. As ingrowth materials with inter-connecting porosity (i.e., velours, ~elts, foams, sponges1 can conduct bacterial infection once established, such materials will incorporate an antibacterial agent to prevent bacterial "wicking." Additionally, it is desirable to use biodegradable materials for the ingrowth layer, so that when catheter removal is indicated, the ingrowth material can be left in situ for resorbtion, thereby alleviating the need for surgical excision. Some potential resorbable materials are collagen, polypeptide, polylactic acid, and polyamino acids. Surface texturing can be used in combination with incorporation of antibacterial activity into or onto the sleeve material as previously described-The thickness, inside diameter and outside diameterof the sleeve 5 will depend on the outside diameter of the conduit and its radial compliance, the properties of ~5~3~
1 the sleeve material, and the coe~ficient of friction between the conduit outer surface and the sleeve inner surface.
That is to say, the dimensions of a compliant sleeve material are less critical than in material which is less compliant. Also, the greater the coefficient of friction of either the conduit or sleeve, the less the sleeve will tend to slide longitudinally on the conduit; there will therefore be a correspondingly reduced need for radial compression of the conduit by the sleeve to fix the latter in place.
The thickness of an attached porous ingrowth layer 7 will depend on the outside diameter of the sleeve, the expected loads on the percutaneous interface, the degradation rate of the ingrowth layer if it is bio-degradable, and the intended period of clinical use.
Another component of the present invention is an introducer 8, to position the device. Introducer 8 is designed to dilate sleeve 5 to allow its positioning Z over conduit 1~ The following examples are given for illustrative purposes. Figures 6 and 7 show a cylindrical introducer 8 with a taper 9 at one end, a flange 10 on the other end, and perforation lines 11 along the length of the introducer radially opposed to each other. The perforation lines enable the introducer to be split into two sections either before installation in the sleeve, or during removal from the sleeve.
Introducer 8 is preferably manufactured in two seuarate pieces, one of which is shown in end and edge views in Figures 6b and 6c respectively. In using this introducer 8, the two halves are placed together as shown in Figure 6d. The tapered end 9 of introducer 8 is then pushed into sleeve S, dilating it, and the ~2~5g3~
1 assembly of introducer ~ and sleeve 5 is pushed onto conduit 1 as shown in Figure 7. When sleeve S is correctly positioned, the two halves of introducer 8 are pulled apart, causing its removal from within sleeve 5. An advantage of the two-piece design is that introducer 8 may be easily removed from the site of conduit implantation without threading the length of of the conduit through the introducer. Introducer 8 may be formed of a plastic material or of metal, but it is preferred that the material be slightly flexible. An advantage o~ using a plastic material is that introducer 8 may be both sterile and disposable.
An alternate embodiment of an introducer as shown in Figures 8A and 8B using two components joined at a pivot ll, would allow the sleeve to be placed over the split cylinder sections, 12 and 13, and dilated when pressure is applied to the actuation pads 14 and 15.
The introducer and sleeve is placed over the catheter or conduit, and brought to the desired location. The pressure on the actuation pads is released as the introducer is pulled away from the sleeve, leaving the sleeve on the conduit.
Any rigid polymer which is readily sterilizable and moldable would be suitable for the construction of the introducer. Some examples are polyethylene, poly-propylene, and polysulfone. An introducer design such as described in Figures 6, 7 and 8 is not permanently deformed during use, and can be reused. A variety of metals and rigid polymers are suitable for its construction-3~
1 Alternate Embodiments of the Invention . _ Alternative sleeve-like designs utilizing elastic components to provide residual clampiny force for fixation are possible, combined with the tissue sealing components and the incorporation of antibacterial activity as previously described.
A composite device design utilizing elastomeric components 16, in Figure 9, to provide positionability of the device is a simple modification although device complexity is increased. Such a sleeve may be formed in two parts: an elastomeric region 16A and a non-distensible region 16B, bonded to elastomeric region 16A.
A sleeve design with a "C" shaped cross-section, or similar, when deformed (Figure 10~, could be placed over a conduit without high dilation through the opening 17, to the lumen 18. Release of the device will allow elastic return to apply a clamping force, although not as efficiently as an integral, cylindrical sleeve.
This embodiment of the present invention can be used with the introducers 6 or 8 already described.
A design shown in Figure 11 which consists of a strip of material wound into a helical sleeve-could be deformed and placed around a catheter-like tube without high material deformation, yet utilizing the deformation to provide a residual clamping force, although the magnitude of the force will not be as great as in the designs of Figures 2, 3, 4, and 5. The design of the embodiment shown in Figure 12 does not require use of an introducer.
Finally, it should be emphasized that these designs may also be used to secure conduits in wholly intra-corporeal sites, as for example when electrical leads I
~2~sg3~
15974 -15- ~
1 need to be implanted~in regions of high mobility such as joints, blood vessels~ the heart, or in the bowel.
While the present invention has been disclosed in terms of a number of specific embodiments, these embodiments are not intended to limit the scope of the invention as alternatives to them will be readily apparent to one with ordinary skill in this art.
V62:15794/DJM/RRP -1-A POSITIONABLE TISSUE INTERFACING DEVICE FOR
THE MANAGEMENT OF PERCUTANEOUS CONDUITS
Field of the Invention This invention relates to a device for the improved management of microbial invasion associated with percu-taneous conduits, but more particularly to a design which allows the device to be used in conjunction with an existing conduit and positioned along the length of the conduit to the desired anatomical site for optimal effectiveness.
Description of the Prior Art A percutaneous device or conduit is an implement which passes through the skin, allowing the linkage of an intracorporeal organ or cavity with extracorporeal equipment. There exists a wide variety of clinical applications for percutaneous devices. In the facilita-tion of fluid transport, percutaneous conduits, or catheters, are used to access blood for dialysis, pressure monitoring, or laboratory diagnosis, to deliver drugs or nutritional solutions, and to drain wound exudate. Percutaneous electrical leads are used to allow the monitoring of biopotentials from natural organs or implanted instrumentation, as well as for stimulation of such organs.
,' l~ .!
~2~S9~
Des?ite the w-despread clinical need and usage o percutaneous conduits, the presence of the conduit eventually results in bacterial infection, compromising the health of the patient and forcing conduit removal.
Thus, the conduit is implanted through a wound in the skin which may have been made expressly for the purpose of inserting the conduit, or may have been the result of injury. In either case a sinus tract is formed by ingrowth of epithelium into the wound A ~ood review of the biology and failure mechanism~
associated with percutaneous devices can be ~oun~ ln CRC Critical Reviews in Bioengineering, Vol. 5, pp. 37-77, 1981, by A.F. von Recum and J. B. Park.
Bacteria that have penetrated beneath the epithelium-conduit interface into underlying tissues find a favorable environment for colonization. The tissues contacting implanted foreign bodies are in a state of chronic inflammation, impairing the normal deense mechanisms against bacterial infection, a basis for the commonly accepted fact that wounds containing foreign boZies are more susceptible to infection.
(Williams and Road, Implants in Surgery, 2~1-244, W. B.
Saunders Co., Ltd., 1973.) A classic study demonstrated that while 7.5 x 106 viable staph aureus organisms were necessary to ?roduce a skin infection, only 3 x 102 organisms produced an infection in the presence ~2~5931 1 of a silk sti~ch inserted in the wound. ~Elek and Conen, British Journal of Experimental Pathology, 38:573, (1957).] A more recent study has indicated the phagocytosis of bacteria by leukocytes, the secondary defense against bacterial invasion, is impaired in the presence of some foreign materials, at least in vitro.
(Borges, L.F., Neurosurgery, 10:55-60, 1982) Typically, once established, bacterial infections around implanted foreign materials cannot be managed, even with massive antibiotic therapy, forcing removal of the implant.
The advance of bacterial colonization along the conduit surface and interfacing tissues may also result in peritonitis when the peritoneal cavity is penetrated by the conduit. Similarly, joint capsule infection may occur when a wound is drained after orthopedic surgery, and septicemia may result when the vascular system is accessed by an intravenous or arterial line. The constant bacterial challenge and threat of infection created by percutaneous conduits forces conduit removal and replacement in alternate areas when possible, and either discontinuation of the function of the conduit or increased risk of infection when not possible.
The bacterial organisms which initiate infections associated with percutaneous conduits are part of the normal flora on the skin, ranging in density from 10 to 106 organisms per square centimeter. Normally these organisms are unable to colonize illtO deeper tissues and proliferate, as they cannot penetrate the primary barrier against infection, the epidermal layer of the skin. The presence of a percutaneous conduit requires disruption of this barrier, through which bacteria can invadc deeper tissues.
5~
1 The perimeter at the conduit in~erface does not seal, even after sufficient time for wound healing. The new, healing epithelium, upon reaching the condui~, does not recognize and adhere to the foreign body, but instead, grows down along the conduit in an effort to externalize the foreign body, forming a sinus tract, a pathway for bacterial invasion. A recent clinical study has indicated significant association of bacterial colonization of percutaneous catheters and the density of bacteria present on the skin at the exit site, as one would expect from the infection pathway. (Bjornson, et al., Surgery, Vol. 92, No. 4, pp. 720-726, 1982).
The lack of a seal at the conduit to the dermal and epidermal tissues not only allows access for bacteria, but also prevents mechanical loads from being transferred between the tissues and the conduit. The mechanical discontinuity causes a crevice between the tissues and a conduit to open and close when the conduit is mechanically stressed or when the tissues move during normal muscle usage, promoting bacterial invasion.
In order to reduce the ever-present threat of infection associated with percutaneous conduits, devices to improve the tissue interface at the percutaneous area (dermis- and epidermis-conduit interface) have been constructed. The use of porous material which promotes tissue in~rowth in the tissue layers below the epidermis has shown effectiveness in inhibiting epidermal downgrowth (sinus tract formation) and promoting a seal at the epidermal- and dermal-conduit interface. (Lee, U.S. Pat.
3,663,965; Borsany, U.S. Pat. 4,278,092.) However, porous materials with interconnected porosity, such as velours, felts, foams, and sponges, have a disadvantage in that once infected, the material acts as a wick, ~5~3~
l allowing the bacteria to colonize the pores f illed with wound exudate and wound debris, in areas not readily accessible to host defense cells.
Other attempts at combating bacterial infection related to percutaneous conduits involve the application of antibacterial agents, either to the conduit surface (Crossley, U.S. Pat. 4,054,139), or in a fluid reservoir device constructed around the conduit, located in the subcutaneous tissue just below the conduit exit site (Kitrilakis, et al., U.S. Pat. 3,699,956).
Several problems arise when using a tissue inter-facing device at the percutaneous interface to help reduce the incidence of infection. The use of devices which have bulky subcutaneous flanges (Faso, U.S. Pat.
4,217,664) or antibacterial fluid reservoirs (Kitrilakis, supra) require surgical manipulation of tissues to properly place the device. If the device has a tissue sealing design using porous materials, such as a velour sleeve, the material should be located close to the dermis-conduit interface. Misplacement in the intracorporeal direction will allow mechanical discontinuity at the critical dermis-to-conduit interface, and also will not allow the epidermis and dermis to grow into the porous material to provide a bacterial seal. Misplacement in the extra-corporeal direction will create passageways for bacteria through the pores and immediately introduce external skin bacteria to colonize the porous material.
Also, when implanting a percutaneous conduit with an attached percutaneous device, or otherwise designated percutaneous area, the length of conduit frorn the percutaneous exit site to the intracorporeal end is desired to be variable, to allow for the anatomical geometry of the particular patient. Inaccuracies ,, .
3LZ~3~L
involved in estimating tllis length may cause the improper location of the percutaneous tissue-interfacing device in the tissue layers of the integuement, the improper location of the intracorporeal end, undesirable slack in the conduit, or required trial fittings to establish the correct length.
The percutaneous tissue-interfacing device of this invention is easily positionable along the conduit length to provide flexibility for optimal device placement during the surgical procedure. ~dditionally, the ability to be quickly positioned and attached to a pre-existing percu-taneous conduit allows the device to be used as an optional measure for patients at high risk for infection.
Summary of the Invention The invention comprises a tissue interface device designed to be placed onto a separate percutaneous conduit and positioned along the conduit length to a desired anatomical site for effective infection resistanceO The invention can be implemented at the time of conduit implantation, or at a later time at the discretion of the clinical practitioner.
Briefly, the invention comprises a sleeve with elastic properties which is dilated with the aid of a special introducer and is then placed over a conduit or catheter-like device. When the introducer is removed, the elastomeric properties of the sleeve material cause its diameter to decrease resulting in radial compression against the conduit, thus securing the sleeve.
The outer, tissue interfacing 5urface of the device is designed to reduce the incidence of infection related ~ z~g~
1597~ -7-to percutaneous conauits by two basic mechanisms:
(a) promotion of a tissue-to-conduit seal at the skin (epidermis, dermis, and adjacent subcutaneous tissues3 to conduit interface, and (b) the use of antibacterial agents incorporatea into the device to reduce the possibility of bacteria colonizing the foreign materials (especially during the initial ~ormation of ~ tissue seal) and advancing along the conduit into deeper - tissues.
, Description of the ~rawings Fig. 1 shows the anatomical relationship between a percutaneous conduit; the skin and the body sur~ace;
Fig. 2 illustrates the relationship between a conduit, a sleeve and an introaucer;
Fig. 3 shows how a sleeve is positioned by an introducer on a conduit;
Figa 4 shows differently shaped conduits in cross section;
Fig. 5 is a drawing of a conduit with longitudinally placed tissue ingrowth material, Fig. 6 shows one type of introducer;
Fig. 7 illustrates the use of an introducer of the type shown in Figure 6;
Fig. 8 illustrates an alternative embodiment of an introducer;
Fig. 9 shows one alternative embodiment of the sleeve of Figure 2;
Fig. 10 shows another alternative embodiment of a sleeve; and Fig. 11 shows yet another embodiment of a sleeve, where the sleeve is wound around the conduit.
g~2~5~33~
For clarity, Figure 1 depicts the anatomical relationships referred to in the following description of the infection mechanism associated with percutaneous conduits. A conduit 1 is showing spanning the Yarious layers of the skin 2. The portion of the conduit 1 which lies outside the body is referred to as extra-corporeal, while that within the body body is intra-corporeal. Conduit 1 is implanted through a wound in the skin; wound 3 may have been made expressly for the purpose of inserting conduit 1, or it may have been the result of an injury. In either case, a sinus tract 4 is formed by ingrowth of epithelium into the wound.
5~3~
15974 _9_ 1 Description of the Preferred Embodiments Referring to Figure 2, the preferred embodiment device of the present invention includes a sleeve 5, with an inside diameter less than the outside diameter of a conduit, 1. The term "conduit" is used in a general sense to include both hollow tubular catheters and other types of elongated body-insertable members (either solid or hollow) such as electrical leads.
The device is elastically dilated by way of an introducer 6. Introducer 6, which will be described in greater detail below, is inserted into the sleeve 5, and used to expand its diameter. The externally extending conduit end is inserted through the introducer 6 and distended sleeve 5, and the sleeve and introducer are moved longitudinally along this conduit to the desired tissue site. Introducer 6 is then removed, allowing sleeve 5 to return to its normal diameter, leaving the tissue-interfacing sleeve clamped onto the conduit.
Sleeve 5 will typically be located in a subcutaneous position, as illustrated in Figure 3B, where sleeve 5 is shown serving to secure a percutaneous conduit.
Figure 3 illustrates the relationship of conduit 1, sleeve 5 and an alternative embodiment of an introducer 8 ~shown in detail below). In Figure 3A the assembled introducer 8 and sleeve 5 are shown as they are placed over the extracorporeal conc1uit 1 in preparation for positioning. In Figure 3~, sleeve 5 has been positioned with respect to skin 2. Introducer 8, still in place, will be removed, leaving sleeve 5 in place around conduit 1. Although this illustration shows one design of introducer, the same relationships between skin, conduit, sleeve and introducer would obtain were an introducer of a diferent design used.
5~3~
1597~ -~0-1 Essential to the positionability of the device is the elastic property of the sleeve material. This allows high material strain, corresponding to large device dilation, and use of the stored strain energy to provide a radial clamping force upon release~ The high deformability of the elastomeric material also allows sealing of sleeve 5 to the conduit 1, even if the conduit cross-section is ellipsoid (Fig. 4a) or has complex geometry (Fig. 4b, 4c). Any elastomer with negligible stress-relaxation properties and high elastic limit is suitable mechanically. It is also desirable from a physiological viewpoint that the elastic material have minimal inflammatory effect on the surrounding tissue.
Several t~pes of medical grade elastomers, such as polydimethyl siloxanes (silicone rubbers) or related polymers, polyurethanes and polyisoprenes are suitable.
Essential to the infection reduction properties of the invention is the outer, tissue interfacing surface of sleeve 5. The surface is desired to express both antibacterial activity and tissue sealing properties.
The tissue sealing properties can be conferred by (a) the attachment of porous, tissue ingrowth promoting material, such as woven felts, and velours, textured polymers, and foam or sponge-like materials, (2) the surface texturing of the sleeve material by high energy bombardment or salting out methods; (3) the attachment or incorporation of tissue adhesive biomolecules such as lectins.
The antibacterial properties can be conferred by (1) bulk incorporation of antibacterial agent into the sleeve material, (2) surface coating of antibacterial agent, or (3) attachment of a tissue ingrowth promoting material with incorporated antibacterial activity.
593~
1 Generally, the invention will consist of a sleeve 5, with antibacterial surface properties conferred by one of the methods previously described. It is also preferred to have tissue adhesive properties without the use of rclatively permanent porous tissue ingrowth materials.
The use of adhesive biomolecules on the outer surface or biodegradable tissue in9rowth materials such as collagen sponge, or a combination of the two, are preferred, as ease of device removal will not become compromised.
In one embodiment of the present invention, shown in Figure 5, sleeve 5 will have an irregular-surfaced tissue ingrowth material 7, attached placed on the outer surface in longitudinal strips or sufficient radial dilation. The ingrowth of subcutaneous and dermal tissue into the pores will form a seal around the conduit, reducing the sinus tract pathway for bacterial invasion around the catheter. As ingrowth materials with inter-connecting porosity (i.e., velours, ~elts, foams, sponges1 can conduct bacterial infection once established, such materials will incorporate an antibacterial agent to prevent bacterial "wicking." Additionally, it is desirable to use biodegradable materials for the ingrowth layer, so that when catheter removal is indicated, the ingrowth material can be left in situ for resorbtion, thereby alleviating the need for surgical excision. Some potential resorbable materials are collagen, polypeptide, polylactic acid, and polyamino acids. Surface texturing can be used in combination with incorporation of antibacterial activity into or onto the sleeve material as previously described-The thickness, inside diameter and outside diameterof the sleeve 5 will depend on the outside diameter of the conduit and its radial compliance, the properties of ~5~3~
1 the sleeve material, and the coe~ficient of friction between the conduit outer surface and the sleeve inner surface.
That is to say, the dimensions of a compliant sleeve material are less critical than in material which is less compliant. Also, the greater the coefficient of friction of either the conduit or sleeve, the less the sleeve will tend to slide longitudinally on the conduit; there will therefore be a correspondingly reduced need for radial compression of the conduit by the sleeve to fix the latter in place.
The thickness of an attached porous ingrowth layer 7 will depend on the outside diameter of the sleeve, the expected loads on the percutaneous interface, the degradation rate of the ingrowth layer if it is bio-degradable, and the intended period of clinical use.
Another component of the present invention is an introducer 8, to position the device. Introducer 8 is designed to dilate sleeve 5 to allow its positioning Z over conduit 1~ The following examples are given for illustrative purposes. Figures 6 and 7 show a cylindrical introducer 8 with a taper 9 at one end, a flange 10 on the other end, and perforation lines 11 along the length of the introducer radially opposed to each other. The perforation lines enable the introducer to be split into two sections either before installation in the sleeve, or during removal from the sleeve.
Introducer 8 is preferably manufactured in two seuarate pieces, one of which is shown in end and edge views in Figures 6b and 6c respectively. In using this introducer 8, the two halves are placed together as shown in Figure 6d. The tapered end 9 of introducer 8 is then pushed into sleeve S, dilating it, and the ~2~5g3~
1 assembly of introducer ~ and sleeve 5 is pushed onto conduit 1 as shown in Figure 7. When sleeve S is correctly positioned, the two halves of introducer 8 are pulled apart, causing its removal from within sleeve 5. An advantage of the two-piece design is that introducer 8 may be easily removed from the site of conduit implantation without threading the length of of the conduit through the introducer. Introducer 8 may be formed of a plastic material or of metal, but it is preferred that the material be slightly flexible. An advantage o~ using a plastic material is that introducer 8 may be both sterile and disposable.
An alternate embodiment of an introducer as shown in Figures 8A and 8B using two components joined at a pivot ll, would allow the sleeve to be placed over the split cylinder sections, 12 and 13, and dilated when pressure is applied to the actuation pads 14 and 15.
The introducer and sleeve is placed over the catheter or conduit, and brought to the desired location. The pressure on the actuation pads is released as the introducer is pulled away from the sleeve, leaving the sleeve on the conduit.
Any rigid polymer which is readily sterilizable and moldable would be suitable for the construction of the introducer. Some examples are polyethylene, poly-propylene, and polysulfone. An introducer design such as described in Figures 6, 7 and 8 is not permanently deformed during use, and can be reused. A variety of metals and rigid polymers are suitable for its construction-3~
1 Alternate Embodiments of the Invention . _ Alternative sleeve-like designs utilizing elastic components to provide residual clampiny force for fixation are possible, combined with the tissue sealing components and the incorporation of antibacterial activity as previously described.
A composite device design utilizing elastomeric components 16, in Figure 9, to provide positionability of the device is a simple modification although device complexity is increased. Such a sleeve may be formed in two parts: an elastomeric region 16A and a non-distensible region 16B, bonded to elastomeric region 16A.
A sleeve design with a "C" shaped cross-section, or similar, when deformed (Figure 10~, could be placed over a conduit without high dilation through the opening 17, to the lumen 18. Release of the device will allow elastic return to apply a clamping force, although not as efficiently as an integral, cylindrical sleeve.
This embodiment of the present invention can be used with the introducers 6 or 8 already described.
A design shown in Figure 11 which consists of a strip of material wound into a helical sleeve-could be deformed and placed around a catheter-like tube without high material deformation, yet utilizing the deformation to provide a residual clamping force, although the magnitude of the force will not be as great as in the designs of Figures 2, 3, 4, and 5. The design of the embodiment shown in Figure 12 does not require use of an introducer.
Finally, it should be emphasized that these designs may also be used to secure conduits in wholly intra-corporeal sites, as for example when electrical leads I
~2~sg3~
15974 -15- ~
1 need to be implanted~in regions of high mobility such as joints, blood vessels~ the heart, or in the bowel.
While the present invention has been disclosed in terms of a number of specific embodiments, these embodiments are not intended to limit the scope of the invention as alternatives to them will be readily apparent to one with ordinary skill in this art.
Claims (12)
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An implantable device for providing a circumferential bacterial seal and sutureless tissue fixation to a percutaneous conduit of known outside diameter, comprising a distensible elastomeric sleeve having a relaxed inside diameter smaller than said known diameter, and having sufficient resiliency to enable forcible expansion of the inside diameter so the sleeve can be moved along the conduit into an implanted intracorporeal position beneath a skin exit site at any desired longitudinal position along the conduit, the resiliency of the sleeve providing a restoring force sufficient to place the sleeve in frictional gripping contact with the conduit at said position when the expanding force is removed, the sleeve being formed of a tissue-compatible material and having an outer surface which promotes tissue ingrowth.
2. The device of claim 1 wherein the surface of the sleeve has been impregnated with a substance having antibacterial properties.
3. The device of claim 1 wherein only a portion of the circumference of the sleeve is distensible.
4. The device of claim 1 wherein the circumference of the sleeve is incomplete.
5. The device of claim 1 wherein the sleeve is fomred as a helical coil to be wound around the conduit.
16 '
16 '
6. The device of claim 1 wherein the tissue-ingrowth-promoting surface of the sleeve is provided by a material secured to the sleeve outer surface.
7. The device of claim 1 wherein the tissue-ingrowth material is impregnated with a substance having anti-bacterial properties.
8. The device of claim 7 wherein the material attached to the outer surface of the sleeve is selected from the group consisting of velour, felt, foam, sponge, collagen, polylactic acid, polyamino acid, and polypeptide.
9. The device of claim 1 wherein the inner surface of the sleeve contacting the percutaneous conduit contains an antimicrobial agent, combined with a sleeve clamping force that allows limited motion of the percutaneous conduit, thereby inactivating bacteria on the outer surface of the perctaneous conduit as it passes through the sleeve to provide an aseptic sliding seal.
10. The combination comprising a percutaneously inserted conduit having an intracorporeal portion for extending beneath a skin exit site, and an elastomeric sleeve in resiliently gripping engagement around the intracorporeal portion of the conduit and resisting longitudinal movement along the conduit, the sleeve being sufficiently elastic to enable forced dilation so the sleeve can be enlarged in inside diameter and slipped along the conduit to a desire subcutaneous position after conduit implantation, the sleeve having an outer surface which promotes tissue ingrowth.
11. The device of claim 10 wherein the tissue ingrowth material is comprised of cross-linked collagen sponge.
12. The device of claim 10 wherein the tissue ingrowth material contains an antimicrobial agent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65344284A | 1984-09-21 | 1984-09-21 | |
US653,442 | 1984-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1245931A true CA1245931A (en) | 1988-12-06 |
Family
ID=24620914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000490636A Expired CA1245931A (en) | 1984-09-21 | 1985-09-13 | Positionable tissue interfacing device for the management of percutaneous conduits |
Country Status (10)
Country | Link |
---|---|
US (1) | US4676782A (en) |
EP (1) | EP0196323B1 (en) |
JP (1) | JPH064095B2 (en) |
AT (1) | ATE71542T1 (en) |
AU (1) | AU4960785A (en) |
CA (1) | CA1245931A (en) |
DE (1) | DE3585230D1 (en) |
FR (1) | FR2574300B1 (en) |
GB (1) | GB2175214B (en) |
WO (1) | WO1986001729A1 (en) |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4955890A (en) * | 1986-01-16 | 1990-09-11 | Vitaphore Corporation | Surgical skin incision device, percutaneous infection control kit and methods of use |
US4886502A (en) * | 1986-12-09 | 1989-12-12 | Thermedics, Inc. | Peritoneal access catheter |
US4863426A (en) * | 1987-08-18 | 1989-09-05 | Ferragamo Michael C | Percutaneous venous catheter |
US4931282A (en) * | 1987-11-25 | 1990-06-05 | Minnesota Mining And Manufacturing Company | Pressure-sensitive medical sealant |
US4834712A (en) * | 1988-01-15 | 1989-05-30 | Corpak, Inc. | Tube fixation device |
US4903707A (en) * | 1988-04-22 | 1990-02-27 | Camino Laboratories | Ventricular catheter assembly |
JPH03505285A (en) * | 1988-05-02 | 1991-11-21 | スベンソン,ヤン アクセル | transplant passageway |
US4959054A (en) * | 1988-11-23 | 1990-09-25 | Clemson University | Pharmaceutically protected percutaneous devices |
EP0431102A4 (en) * | 1989-06-02 | 1992-01-08 | Baxter International Inc. | Porous percutaneous access device |
US5203770A (en) * | 1990-04-20 | 1993-04-20 | Regents Of The University Of Minnesota | Method and apparatus for catheterization |
US5120312A (en) * | 1990-04-20 | 1992-06-09 | Regents Of The University Of Minnesota | Method and apparatus for catheterization |
US5766249A (en) * | 1990-11-20 | 1998-06-16 | Griffith; Donald P. | Tissue bondable cystostomy tube and method of cystostomy tube implantation |
US5234408A (en) * | 1990-11-20 | 1993-08-10 | Griffith Donald P | Tissue bondable cystostomy tube and method of cystostomy tube implantation |
US5112310A (en) * | 1991-02-06 | 1992-05-12 | Grobe James L | Apparatus and methods for percutaneous endoscopic gastrostomy |
US5236422A (en) * | 1991-06-24 | 1993-08-17 | Eplett Jr James D | Antiseptic urinary catheter cuff |
US5215530A (en) * | 1991-07-11 | 1993-06-01 | City Of Hope | Sleeved extension and anchoring system for percutaneous catheters |
US5141499A (en) * | 1991-10-09 | 1992-08-25 | Zappacosta Anthony R | Peritoneal dialysis catheter |
US5352207A (en) * | 1992-05-18 | 1994-10-04 | Nussbaum Eric S | Ventricular drainage catheter with guard |
GR930100244A (en) * | 1992-06-30 | 1994-02-28 | Ethicon Inc | Flexible endoscopic surgical port |
NZ250214A (en) * | 1992-12-23 | 1995-10-26 | Ndm Acquisition Corp | Deep wound dressing and syringe therefor |
US5308338A (en) * | 1993-04-22 | 1994-05-03 | Helfrich G Baird | Catheter or the like with medication injector to prevent infection |
US5476493A (en) * | 1993-05-19 | 1995-12-19 | Pacesetter, Inc. | Implantable lead having self-locking suture sleeve |
US5383896A (en) * | 1993-05-25 | 1995-01-24 | Gershony; Gary | Vascular sealing device |
US6017359A (en) * | 1993-05-25 | 2000-01-25 | Vascular Solutions, Inc. | Vascular sealing apparatus |
US5868778A (en) * | 1995-10-27 | 1999-02-09 | Vascular Solutions, Inc. | Vascular sealing apparatus and method |
FR2722413B1 (en) * | 1994-07-13 | 1997-02-07 | Marian Devonec | THERAPEUTIC IMPLANT INTENDED FOR THE SELECTIVE CYTOREDUCTIVE TREATMENT OF LIGHT OR NATURAL PATH OBSTRUCTION OF A HUMAN OR ANIMAL BODY |
US5569207A (en) * | 1994-10-13 | 1996-10-29 | Quinton Instrument Company | Hydrocolloid dressing |
US5554106A (en) * | 1994-10-13 | 1996-09-10 | Quinton Instrument Company | Hydrocolloid exit site dressing |
US6616675B1 (en) * | 1996-02-02 | 2003-09-09 | Transvascular, Inc. | Methods and apparatus for connecting openings formed in adjacent blood vessels or other anatomical structures |
US5830184A (en) * | 1996-03-06 | 1998-11-03 | Medical Components, Inc. | Composite catheter stabilizing devices, methods of making the same and catheter extracting device |
US6361541B1 (en) | 1998-07-17 | 2002-03-26 | The University Of Iowa Research Foundation | Surgical instrument for extracting tissue ingrowth from a permeable member of an implanted catheter |
IT1306197B1 (en) * | 1999-01-12 | 2001-05-30 | Michelina Tricarico | DEVICE FOR DRAINAGE OF EXUDING MATERIAL FROM AN ENDOCORPOREAL CAVITY OF A PATIENT. |
EP1027867A1 (en) * | 1999-02-09 | 2000-08-16 | Berger AG | Device for holding a cannula and method of manufacturing said device |
US6168580B1 (en) | 1999-03-26 | 2001-01-02 | Iontophoretics Corporation | Antimicrobial device and methods for long-term catheters |
US6692494B1 (en) * | 1999-08-05 | 2004-02-17 | Broncus Technologies, Inc. | Methods and devices for creating collateral channels in the lungs |
US7422563B2 (en) * | 1999-08-05 | 2008-09-09 | Broncus Technologies, Inc. | Multifunctional tip catheter for applying energy to tissue and detecting the presence of blood flow |
US7462162B2 (en) | 2001-09-04 | 2008-12-09 | Broncus Technologies, Inc. | Antiproliferative devices for maintaining patency of surgically created channels in a body organ |
US7175644B2 (en) * | 2001-02-14 | 2007-02-13 | Broncus Technologies, Inc. | Devices and methods for maintaining collateral channels in tissue |
US7361158B1 (en) * | 1999-09-24 | 2008-04-22 | Medicinvent, Llc | Catheter including textured interface |
US6363273B1 (en) | 1999-12-22 | 2002-03-26 | Codman & Shurtleff, Inc. | Introducer element and method of using same |
US6451003B1 (en) * | 2000-08-16 | 2002-09-17 | Biolink Corporation | Method and apparatus for overcoming infection in a tissue pocket surrounding an implanted device |
US8251986B2 (en) | 2000-08-17 | 2012-08-28 | Angiodynamics, Inc. | Method of destroying tissue cells by eletroporation |
US20030083539A1 (en) * | 2000-11-17 | 2003-05-01 | Boris Leschinsky | Intra-aortic balloon catheter for long-term implantation |
US6607504B2 (en) | 2001-06-29 | 2003-08-19 | Scimed Life Systems, Inc. | Percutaneous access |
AU2002322599A1 (en) | 2001-07-27 | 2003-02-17 | Mark A. Saab | Medical device with adjustable epidermal tissue ingrowth cuff |
US6994706B2 (en) | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
US7708712B2 (en) | 2001-09-04 | 2010-05-04 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
US8579937B2 (en) * | 2002-07-31 | 2013-11-12 | Covidien Lp | Tool member cover and cover deployment device |
US6916310B2 (en) * | 2003-05-30 | 2005-07-12 | Codman & Shurtleff, Inc. | Percutaneous access device |
US8308682B2 (en) | 2003-07-18 | 2012-11-13 | Broncus Medical Inc. | Devices for maintaining patency of surgically created channels in tissue |
US8409167B2 (en) | 2004-07-19 | 2013-04-02 | Broncus Medical Inc | Devices for delivering substances through an extra-anatomic opening created in an airway |
US20060036215A1 (en) * | 2004-08-12 | 2006-02-16 | Mikhail Boukhny | Surgical apparatus |
GB0421164D0 (en) * | 2004-09-23 | 2004-10-27 | Univ Nottingham | Medical devices and methods of making medical devices |
CA2586398A1 (en) * | 2004-12-21 | 2006-06-29 | C.R. Bard, Inc. | Hemostasis cuff for catheter securement |
US8252016B2 (en) | 2005-01-13 | 2012-08-28 | Azam Anwar | System and method for providing embolic protection |
US7976518B2 (en) | 2005-01-13 | 2011-07-12 | Corpak Medsystems, Inc. | Tubing assembly and signal generator placement control device and method for use with catheter guidance systems |
WO2006079055A2 (en) * | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
US20060200168A1 (en) * | 2005-03-03 | 2006-09-07 | Azam Anwar | System and method for providing access in divergent directions in a vascular environment |
US8100863B2 (en) | 2005-03-04 | 2012-01-24 | C. R. Bard, Inc. | Catheter assembly, catheter systems including same, and method of manufacture |
US20060253104A1 (en) | 2005-04-20 | 2006-11-09 | Boston Scientific Scimed, Inc. | Access and drainage devices and methods of use thereof |
US20070066966A1 (en) * | 2005-10-03 | 2007-03-22 | Christopher Davey | Implantable medical device |
US8267905B2 (en) * | 2006-05-01 | 2012-09-18 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
ATE482647T1 (en) * | 2006-05-16 | 2010-10-15 | Wilson Cook Medical Inc | BALLOON CUFF |
US7803148B2 (en) * | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
CA2594239A1 (en) * | 2006-08-02 | 2008-02-02 | Tyco Healthcare Group Lp | Stabilization assist device for trocar |
US7947019B2 (en) * | 2006-08-18 | 2011-05-24 | Angio Dynamics, Inc | Catheter retention assembly and method of use |
US7798998B2 (en) * | 2006-10-06 | 2010-09-21 | Surgiquest, Inc. | Elastically deformable surgical access device |
US7806870B2 (en) * | 2006-10-06 | 2010-10-05 | Surgiquest, Incorporated | Elastically deformable surgical access device having telescoping guide tube |
US10188826B2 (en) * | 2006-09-29 | 2019-01-29 | Covidien Lp | Catheters including antimicrobial sleeve and methods of making catheters |
WO2010042913A2 (en) * | 2006-10-06 | 2010-04-15 | Surgiquest, Incorporated | Devices for and methods of performing minimally-invasive surgical procedures through a single incision |
JP5269808B2 (en) * | 2006-12-28 | 2013-08-21 | アエク メディカル、エルエルシー | Antibacterial transcutaneous access shield and kit |
US8430852B2 (en) * | 2007-04-17 | 2013-04-30 | Medtronic, Inc. | Therapeutic sleeve for implantable medical device |
US8597253B2 (en) | 2007-04-20 | 2013-12-03 | Bard Access Systems | Huber needle with safety sheath |
US8864801B2 (en) * | 2007-04-30 | 2014-10-21 | Warsaw Orthopedic, Inc. | Method of deformity correction in a spine using injectable materials |
US20080275401A1 (en) * | 2007-05-01 | 2008-11-06 | Sage Shahn S | Catheter anchor and system/method regarding same |
US8249719B2 (en) | 2007-11-09 | 2012-08-21 | Cardiac Pacemakers, Inc. | Lead stabilizer with retention features |
US8271096B2 (en) | 2007-11-09 | 2012-09-18 | Cardiac Pacemakers, Inc. | Pre-selected compression lead anchoring device |
US20090131919A1 (en) * | 2007-11-21 | 2009-05-21 | Christopher Davey | Implantable medical device |
US8632502B2 (en) | 2008-03-27 | 2014-01-21 | Medtronic, Inc. | Anchor deployment apparatus |
US8262624B2 (en) * | 2008-03-27 | 2012-09-11 | Medtronic, Inc. | Anchor and anchor deployment apparatus |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US10448989B2 (en) | 2009-04-09 | 2019-10-22 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
AU2009243079A1 (en) | 2008-04-29 | 2009-11-05 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US8075531B2 (en) | 2008-07-16 | 2011-12-13 | Marvao Medical Ltd. | Modular implantable medical device |
US20120059335A1 (en) * | 2009-02-10 | 2012-03-08 | INNERSPACE MEDICAL ,INC. a corporation | Flexible Anti-Collapsible Catheter Sleeve |
US8617116B2 (en) | 2009-03-27 | 2013-12-31 | Marvao Medical Devices Ltd. | Deformable medical implant |
US10272236B2 (en) | 2009-03-27 | 2019-04-30 | Marvao Medical Devices Ltd | Deformable medical implant |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9028466B2 (en) * | 2009-06-08 | 2015-05-12 | St. Jude Medical Coordination Center Bvba | Adapter for use in connecting to a first percutaneous introducer |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
US8821455B2 (en) * | 2009-07-09 | 2014-09-02 | Becton, Dickinson And Company | Antimicrobial coating for dermally invasive devices |
US20110065798A1 (en) * | 2009-09-17 | 2011-03-17 | Becton, Dickinson And Company | Anti-infective lubricant for medical devices and methods for preparing the same |
US8377034B2 (en) | 2009-12-04 | 2013-02-19 | Std Med, Inc. | Vascular access port |
US8425455B2 (en) | 2010-03-30 | 2013-04-23 | Angiodynamics, Inc. | Bronchial catheter and method of use |
CA2806393A1 (en) | 2010-09-10 | 2012-03-15 | C.R. Bard, Inc. | Systems for isolation of a needle-based infusion set |
US20140066894A1 (en) | 2010-09-10 | 2014-03-06 | C. R. Bard, Inc. | Self-Sealing Pad for a Needle-Based Infusion Set |
US10525234B2 (en) | 2010-09-10 | 2020-01-07 | C. R. Bard, Inc. | Antimicrobial/haemostatic interface pad for placement between percutaneously placed medical device and patient skin |
US9700368B2 (en) | 2010-10-13 | 2017-07-11 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
EP2667928B1 (en) | 2011-01-28 | 2017-07-12 | Medtronic, Inc | Repositionable therapy delivery element anchor |
JP2014521381A (en) | 2011-05-13 | 2014-08-28 | ブロンカス テクノロジーズ, インコーポレイテッド | Methods and devices for tissue ablation |
US8709034B2 (en) | 2011-05-13 | 2014-04-29 | Broncus Medical Inc. | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
US9028441B2 (en) | 2011-09-08 | 2015-05-12 | Corpak Medsystems, Inc. | Apparatus and method used with guidance system for feeding and suctioning |
US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
WO2013078235A1 (en) | 2011-11-23 | 2013-05-30 | Broncus Medical Inc | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
EP2911737A1 (en) | 2012-10-29 | 2015-09-02 | Cardiac Pacemakers, Inc. | Suture sleeves having exterior surface tear resistance |
US9486622B2 (en) | 2012-11-08 | 2016-11-08 | Cardiac Pacemakers, Inc. | Fixation and strain relief element for temporary therapy delivery device |
US9669190B2 (en) * | 2012-11-28 | 2017-06-06 | Cook Medical Technologies Llc | Selectively positionable catheter cuff |
US9750928B2 (en) | 2013-02-13 | 2017-09-05 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
US9695323B2 (en) | 2013-02-13 | 2017-07-04 | Becton, Dickinson And Company | UV curable solventless antimicrobial compositions |
US9750927B2 (en) | 2013-03-11 | 2017-09-05 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9327095B2 (en) | 2013-03-11 | 2016-05-03 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9364639B2 (en) | 2013-03-15 | 2016-06-14 | Cook Medical Technologies Llc | Moveable cuff |
US20140276606A1 (en) * | 2013-03-15 | 2014-09-18 | Cook Medical Technologies Llc | Moveable cuff |
US9308351B2 (en) * | 2013-05-28 | 2016-04-12 | Smh Device Corp. | Tunneled catheter with hemostasis mechanism |
US9067043B2 (en) * | 2013-05-28 | 2015-06-30 | Smh Device Corp. | Tunneled catheter with hemostasis mechanism |
WO2015020970A1 (en) | 2013-08-09 | 2015-02-12 | Medtronic, Inc. | Anchor sleeve deployment for implantable medical devices |
US10369345B2 (en) | 2014-03-31 | 2019-08-06 | Versago Vascular Access, Inc. | Medical access port, systems and methods of use thereof |
JP6568200B2 (en) | 2014-04-03 | 2019-08-28 | ヴェルサゴ ヴァスキュラー アクセス インコーポレイテッド | Device for attaching and removing the needle tip of a needle |
US10376686B2 (en) | 2014-04-23 | 2019-08-13 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
US9675793B2 (en) | 2014-04-23 | 2017-06-13 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
US9789279B2 (en) | 2014-04-23 | 2017-10-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
US10471254B2 (en) | 2014-05-12 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US10232088B2 (en) | 2014-07-08 | 2019-03-19 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
CN113521503A (en) | 2014-12-01 | 2021-10-22 | 帕夫梅德有限公司 | Self-anchoring catheter and method of use |
WO2016100325A1 (en) | 2014-12-15 | 2016-06-23 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
JP6837971B2 (en) | 2014-12-18 | 2021-03-03 | ヴェルサゴ ヴァスキュラー アクセス インコーポレイテッド | Catheter patency system and method |
AU2015364276B2 (en) * | 2014-12-18 | 2020-04-30 | Versago Vascular Access, Inc. | Devices, systems and methods for removal and replacement of a catheter for an implanted access port |
JP6543721B2 (en) | 2015-05-20 | 2019-07-10 | カーディアック ペースメイカーズ, インコーポレイテッド | Fully integrated lead stabilizer for medical electrical leads and mounting method |
JP6879946B2 (en) | 2015-07-14 | 2021-06-02 | ヴェルサゴ ヴァスキュラー アクセス インコーポレイテッド | Medical access ports, transport devices and how to use them |
US10493244B2 (en) | 2015-10-28 | 2019-12-03 | Becton, Dickinson And Company | Extension tubing strain relief |
US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US10518004B2 (en) | 2016-12-18 | 2019-12-31 | Cardiac Pacemakers, Inc. | Infection fighting drug eluting device |
CN110087726A (en) | 2016-12-18 | 2019-08-02 | 心脏起搏器股份公司 | Anti-infectives elute lead casing |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
CA3086211A1 (en) | 2017-12-21 | 2019-06-27 | Versago Vascular Access, Inc. | Medical access ports, transfer devices and methods of use thereof |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
WO2023014730A1 (en) * | 2021-08-03 | 2023-02-09 | Mcglynn Patrick | Subcutaneous tunneling catheter for peritoneal access |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US271904A (en) * | 1883-02-06 | Inyentoe | ||
US2456257A (en) * | 1946-12-04 | 1948-12-14 | William R Curry | Flushing device for douche syringes |
US3461869A (en) * | 1966-04-05 | 1969-08-19 | Bio Medical Systems Inc | Permanent skin exit device |
US3633585A (en) * | 1969-04-17 | 1972-01-11 | Cutter Lab | Catheter |
US3638649A (en) * | 1969-07-07 | 1972-02-01 | Univ Minnesota | Implantable prosthetic pass-through device |
US3663965A (en) * | 1970-06-08 | 1972-05-23 | Henry L Lee Jr | Bacteria-resistant percutaneous conduit device |
US3699956A (en) * | 1970-10-01 | 1972-10-24 | Tecna Corp | Percutaneous lead device |
US3769975A (en) * | 1971-11-26 | 1973-11-06 | Johnson & Johnson | Slit sleeve for preventing displacement in a catheter assembly |
US3856021A (en) * | 1973-10-01 | 1974-12-24 | A Mcintosh | Device for treatment of bloat of ruminants |
US4054139A (en) * | 1975-11-20 | 1977-10-18 | Crossley Kent B | Oligodynamic catheter |
US4217664A (en) * | 1979-02-02 | 1980-08-19 | Faso Joseph M | Prosthesis and method for creating a stoma |
US4479795A (en) * | 1979-06-29 | 1984-10-30 | The Procter & Gamble Company | Antimicrobial polymer compositions |
US4278092A (en) * | 1979-07-05 | 1981-07-14 | American Hospital Supply Corporation | Peritoneal catheter |
US4266999A (en) * | 1979-07-30 | 1981-05-12 | Calspan Corporation | Catheter for long-term emplacement |
CA1148819A (en) * | 1980-05-08 | 1983-06-28 | Gabor Zellerman | Peritoneal catheter |
US4412832A (en) * | 1981-04-30 | 1983-11-01 | Baxter Travenol Laboratories, Inc. | Peelable catheter introduction device |
US4515593A (en) * | 1981-12-31 | 1985-05-07 | C. R. Bard, Inc. | Medical tubing having exterior hydrophilic coating for microbiocide absorption therein and method for using same |
US4405313A (en) * | 1982-01-29 | 1983-09-20 | Sisley James R | Figure-eight, dual-lumen catheter and method of using |
US4491126A (en) * | 1982-07-06 | 1985-01-01 | Wilbur D. Smith | Method and apparatus for monitoring body parts of animals |
US4484911A (en) * | 1982-09-29 | 1984-11-27 | Berlin Richard B | Cannula and clamp device |
US4539003A (en) * | 1983-01-24 | 1985-09-03 | Tucker Annabelle D | Angio-catheter/infusion tubing lock |
-
1985
- 1985-09-13 CA CA000490636A patent/CA1245931A/en not_active Expired
- 1985-09-20 GB GB08612223A patent/GB2175214B/en not_active Expired
- 1985-09-20 DE DE8585904920T patent/DE3585230D1/en not_active Expired - Fee Related
- 1985-09-20 AT AT85904920T patent/ATE71542T1/en not_active IP Right Cessation
- 1985-09-20 EP EP85904920A patent/EP0196323B1/en not_active Expired - Lifetime
- 1985-09-20 JP JP60504313A patent/JPH064095B2/en not_active Expired - Lifetime
- 1985-09-20 WO PCT/US1985/001809 patent/WO1986001729A1/en active IP Right Grant
- 1985-09-20 AU AU49607/85A patent/AU4960785A/en not_active Abandoned
- 1985-09-23 FR FR858514065A patent/FR2574300B1/en not_active Expired - Lifetime
-
1986
- 1986-05-13 US US06/862,766 patent/US4676782A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1986001729A1 (en) | 1986-03-27 |
DE3585230D1 (en) | 1992-02-27 |
EP0196323A1 (en) | 1986-10-08 |
GB2175214B (en) | 1988-05-18 |
GB8612223D0 (en) | 1986-06-25 |
ATE71542T1 (en) | 1992-02-15 |
EP0196323B1 (en) | 1992-01-15 |
GB2175214A (en) | 1986-11-26 |
FR2574300B1 (en) | 1991-06-21 |
JPS62500434A (en) | 1987-02-26 |
FR2574300A1 (en) | 1986-06-13 |
EP0196323A4 (en) | 1987-06-29 |
AU4960785A (en) | 1986-04-08 |
US4676782A (en) | 1987-06-30 |
JPH064095B2 (en) | 1994-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1245931A (en) | Positionable tissue interfacing device for the management of percutaneous conduits | |
US7331940B2 (en) | Percutaneous access device | |
US6296657B1 (en) | Vascular sealing device and method | |
CA2121847C (en) | Catheter or the like with medication injector to prevent infection | |
US3402710A (en) | Self-closing valve device for implantation in the human body | |
US4790810A (en) | Ureteral connector stent | |
US4623348A (en) | Percutaneous sinus tract maintenance prosthesis | |
JP4519383B2 (en) | Access member and system for bladder catheterization through artificial or natural conduits in a user | |
US5911757A (en) | Methods and apparatus for transcutaneous access | |
ES2308804T3 (en) | A MODULAR PROTESIC DUCT. | |
US3605752A (en) | Catheter guard | |
JPH09234206A (en) | Antibacterial member used as medical or surgical auxiliary means | |
US20220401700A1 (en) | Device for securing a catheter | |
WO2024028628A1 (en) | Blood collection catheter with long-term implantation capability | |
US20220296787A1 (en) | Antimicrobial body access system | |
US11642498B2 (en) | Isolating drainage catheter | |
JPH0430869B2 (en) | ||
CA1245933A (en) | Percutaneous sinus tract maintenance prosthesis | |
CN115887092A (en) | Adjustable postoperative safety tube and using method thereof | |
EP0271613A1 (en) | Improved percutaneous sinus tract maintenance prosthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |